P3 Health Partners Inc. — Form 8-K Summary
Business Context and Reporting Period
Filed December 13, 2022, for events occurring on December 13, 2022. The filing reports a new financing transaction intended to support P3 Health Partners’ ongoing working capital needs. The company operates through P3 Health Partners, LLC, its subsidiary.
Financing, Liquidity, and Key Financial Terms
| Item | Terms |
|---|---|
| Promissory note | Unsecured note providing for up to $40.0 million in three tranches: $15.0 million available immediately, up to $15.0 million by January 5, 2023, and up to $10.0 million by February 3, 2023. |
| Maturity | May 19, 2026. |
| Interest | 14.0% annually, payable quarterly beginning March 31, 2023. The subordination terms effectively require interest to be paid entirely in kind. |
| Fees | 1.5% upfront fee on each draw and a back-end fee ranging from 2.25% to 9.0%, depending on repayment timing. The filing’s text contains an apparent date error for one fee period, stating “December 31, 2021.” |
| Warrants | Warrants to purchase 429,180 Class A common shares at $4.26 per share, expiring December 13, 2027, subject to customary adjustment provisions and earlier termination upon specified transactions. |
The note includes restrictions on additional indebtedness, liens, investments, and restricted payments. It also provides for mandatory prepayments from certain asset sales and potential acceleration upon specified defaults, a change of control, or certain qualified financings.
The note is subordinated to the company’s existing term loan facility. The company amended that facility to permit the new financing and related subordination arrangements.
Material Changes Versus the Prior Comparable Period
- The company entered into a new financing arrangement with VBC Growth SPV LLC, providing potential access to up to $40.0 million.
- The company issued warrants for 429,180 shares of Class A common stock, creating potential dilution.
- VBC is managed by an affiliate of a principal stockholder, and its members include several company directors and executive officers. The transaction was approved by a committee of independent, disinterested directors.
- The transaction addresses an immediate short-term cash need but does not eliminate the previously disclosed going-concern uncertainty.
Outlook, Risks, and Unusual Items
The company previously disclosed that existing cash resources were insufficient to support planned operations and that substantial doubt existed regarding its ability to continue as a going concern. Management stated that the new financing does not change those risks.
The company continues to seek additional debt and equity financing, but stated that such financing may not be available on favorable terms or at all. Management expects continuing net losses, comprehensive losses, and negative operating cash flows under its operating plan.
The financing involves related-party considerations because VBC is affiliated with a principal stockholder and includes company directors and officers among its members. The warrants were issued in an unregistered transaction under Section 4(a)(2) of the Securities Act and/or Regulation D.
Important Facts for Investors to Verify
- Amounts actually drawn under each of the three note tranches and the company’s remaining available borrowing capacity.
- Cash balance, liquidity runway, and going-concern disclosures in subsequent periodic filings.
- The effect of the 14.0% interest rate, in-kind interest accrual, upfront fees, and back-end fee on future obligations.
- Existing term loan balances, covenants, collateral arrangements, and events that could accelerate repayment.
- Potential dilution from the 429,180 warrants and any subsequent equity financing.
- Whether additional capital was obtained and on what terms.
- The apparent “December 31, 2021” date error in the back-end fee schedule and the operative terms in the executed promissory note.